AmpB |
|
Vaxjo ID |
391 |
|
Vaccine Adjuvant Name |
AmpB |
|
Alternative Names |
AmpB is also known as Amphotericin B deoxycholate. |
|
Adjuvant VO ID |
VO_0005530
|
|
Description |
AmpB is an antifungal agent that has immunomodulatory properties. It can stimulate immune responses and has been investigated for its adjuvant potential in vaccines. |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Structure |
It is a polyene macrolide antibiotic. |
|
Appearance |
it is typically a yellowish powder. |
|
Storage |
it is generally stored in a cool, dry place. |
|
Preparation |
AmpB is prepared through fermentation processes using specific strains of Streptomyces species |
|
Function |
Effective immune synergies are essential for the clearance of pathogens, thus inspiring novel adjuvant design to improve vaccines. We highlight current vaccine adjuvants and the importance of immune synergies to adjuvant and vaccine design. The focus is on new technologies used to study and apply immune synergies to adjuvant and vaccine development. |
|
Safety |
AmpB has a known safety profile when used as an antifungal agent, but its safety as a vaccine adjuvant is still under investigation. It can cause side effects such as nephrotoxicity and infusion-related reactions. |
| References |
Tom et al., 2019: Tom JK, Albin TJ, Manna S, Moser BA, Steinhardt RC, Esser-Kahn AP. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development. Trends in biotechnology. 2019; 37(4); 373-388. [PubMed: 30470547].
|
